Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future

Abstract

Hereditary breast and ovarian cancers are most commonly caused by mutations in BRCA1 and 2 genes. These are autosomal dominant mutations with high penetrance into subsequent generations. Affected individuals have deficiency in DNA repair mechanisms such as double strand DNA breaks (DSB) and non-homologous end joining (NHEJ). These tumors are peculiar due to early age of onset, typical histology such as triple negative breast cancers and high grade serous ovarian cancers and exquisite sensitivity to platinum analogues. These patients usually have better survival as compared to their wild type counterparts. Incidence of these mutations is rising due to better awareness about them amongst oncologists and patient population. Various genomic assays are available to detect germline and somatic BRCA mutations. Newer therapeutic frontiers like PARP inhibition have opened up due to better understanding of various mutations and their impact on subsequent pathways. Further studies are required to explore possibility of direct BRCA inhibition which may be useful in treatment of other solid organ cancers as well. This review focuses on understanding the pathophysiology of BRCA mutations, various pathways associated with the same, chemosensitivity patterns amongst affected cancer cells, targeted therapeutic opportunities and potential future developments in this field. We collected data from various published electronic records on google and have no conflicts of interest to be declared.

Keywords

BRCA syndrome - BRCA protein inhibition - chemosensitivity - DNA repair deficiency - PARP inhibitors

Publication History

Received: 08 August 2019

Accepted: 01 September 2020

Article published online:
23 May 2021

• References

• 1 Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: What we know and what we need. Nat Med 2001; 7: 552-6
• 2 Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM. et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011; 108: 18032-7
• 3 Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30
• 4 Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-33
• 5 Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet 1998; 32: 95-121
• 6 Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134-47
• 7 Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z. et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74
• 8 Emborgo T, Muse KI, Bednar E, Oakley HD, Litton JK, Lu KH. et al. Universal BRCA testing and family outreach for women with triple negative breast cancer. Cancer Res 2016; 76 (Suppl. 04) AbstrP2-09-08
• 9 Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 2016; 534: 47-54
• 10 Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A. et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol 2016; 27: 1532-8
• 11 Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake 2nd DD. et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010; 28: 3570-6
• 12 Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol 2016; 27: 1449-55
• 13 Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373: 1697-708
• 14 Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ. et al. Involvement of brca2 in DNA repair. Mol Cell 1998; 1: 347-57
• 15 Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW. et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999; 3: 389-95
• 16 Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C. et al. Embryonic lethality and radiation hypersensitivity mediated by rad51 in mice lacking brca2. Nature 1997; 386: 804-10
• 17 Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E. et al. Tumorigenesis and a DNA repair defect in mice with a truncating brca2 mutation. Nat Genet 1997; 17: 423-30
• 18 Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286: 1162-6
• 19 Gatei M, Zhou BB, Hobson K, Scott S, Young D, Khanna KK. et al. Ataxia telangiectasia mutated (ATM) kinase and ATM and rad3 related kinase mediate phosphorylation of brca1 at distinct and overlapping sites.In vivo assessment using phospho-specific antibodies. J Biol Chem 2001; 276: 17276-80
• 20 Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. HCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000; 404: 201-4
• 21 Yu VP, Koehler M, Steinlein C, Schmid M, Hanakahi LA, van Gool AJ. et al. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev 2000; 14: 1400-6
• 22 Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7: 263-72
• 23 Haber JE. The many interfaces of mre11. Cell 1998; 95: 583-6
• 24 Paull TT, Cortez D, Bowers B, Elledge SJ, Gellert M. Direct DNA binding by brca1. Proc Natl Acad Sci U S A 2001; 98: 6086-91
• 25 Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL. et al. Identification of a RING protein that can interactin vivo with the BRCA1 gene product. Nat Genet 1996; 14: 430-40
• 26 Koonin EV, Altschul SF, Bork P. BRCA1 protein products. Functional motifs. Nat Genet 1996; 13: 266-8
• 27 Huyton T, Bates PA, Zhang X, Sternberg MJ, Freemont PS. The BRCA1 C-terminal domain: Structure and function. Mutat Res 2000; 460: 319-32
• 28 Zhang X, Moréra S, Bates PA, Whitehead PC, Coffer AI, Hainbucher K. et al. Structure of an XRCC1 BRCT domain: A new protein-protein interaction module. EMBO J 1998; 17: 6404-11
• 29 Clark SL, Rodriguez AM, Snyder RR, Hankins GD, Boehning D. Structure-function of the tumor suppressor BRCA1. Comput Struct Biotechnol J 2012; 1: pii e201204005
• 30 Chen JJ, Silver D, Cantor S, Livingston DM, Scully R. BRCA1, BRCA2, and rad51 operate in a common DNA damage response pathway. Cancer Res 1999; 59: 1752s-6
• 31 Bignell G, Micklem G, Stratton MR, Ashworth A, Wooster R. The BRC repeats are conserved in mammalian BRCA2 proteins. Hum Mol Genet 1997; 6: 53-8
• 32 Bork P, Blomberg N, Nilges M. Internal repeats in the BRCA2 protein sequence. Nat Genet 1996; 13: 22-3
• 33 Zhang F, Fan Q, Ren K, Andreassen PR. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 2009; 7: 1110-8
• 34 Bertwistle D, Swift S, Marston NJ, Jackson LE, Crossland S. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001; 114 (20) Pt 3591-8
• 35 Blackshear PE, Goldsworthy SM, Foley JF, McAllister KA, Bennett LM, Collins NK. et al. Brca1 and brca2 expression patterns in mitotic and meiotic cells of mice. Oncogene 1998; 16: 61-8
• 36 Connor F, Smith A, Wooster R, Stratton M, Dixon A, Campbell E. et al. Cloning, chromosomal mapping and expression pattern of the mouse brca2 gene. Hum Mol Genet 1997; 6: 291-300
• 37 Rajan JV, Wang M, Marquis ST, Chodosh LA. Brca2 is coordinately regulated with brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci U S A 1996; 93: 13078-83
• 38 Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G. et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998; 2: 317-28
• 39 Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH. et al. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 1998; 95: 5287-92
• 40 Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR. et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 2001; 7: 273-82
• 41 Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J. et al. Association of BRCA1 with rad51 in mitotic and meiotic cells. Cell 1997; 88: 265-75
• 42 Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int 2013; 2013: 928562
• 43 Menkiszak J, Chudecka-Głaz A, Gronwald J, Bedner R, Cymbaluk-Płoska A, Wezowska M. et al. Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries. Ginekol Pol 2013; 84: 758-64
• 44 Szwiec M, Jakubowska A, Górski B, Huzarski T, Tomiczek-Szwiec J, Gronwald J. et al. Recurrent mutations of BRCA1 and BRCA2 in poland: An update. Clin Genet 2015; 87: 288-92
• 45 Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M. et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-8
• 46 Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B. et al. Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: Implications on test strategies and clinical management. Breast Cancer Res Treat 2012; 134: 1229-39
• 47 Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O. et al. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. Ann Oncol 2011; 22: 964-6
• 48 Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L. et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 2015; 313: 1347-61
• 49 Muggia F, Safra T. ’BRCAness’ and its implications for platinum action in gynecologic cancer. Anticancer Res 2014; 34: 551-6
• 50 Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Autralian ovarian cancer study group. J Clin Oncol 2012; 30: 2654-63
• 51 Gorodnova TV, Sokolenko AP, Ivantsov AO, Iyevleva AG, Suspitsin EN, Aleksakhina SN. et al. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. Cancer Lett 2015; 369: 363-7
• 52 Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016; 16: 110-20
• 53 Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q. et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-53
• 54 Kilburn LS. TNT Trial Management Group. ’Triple negative’ breast cancer: A new area for phase III breast cancer clinical trials. Clin Oncol (R Coll Radiol) 2008; 20: 35-9
• 55 Tutt A, Ellis P, Kilburn LS, Gilett C, Pinder S, Abraham J. et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Abstract S3-01 Presented at the San Antonio Breast Cancer Symposium. San Antonio, TX: 2014: 9-13
• 56 Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97: 2187-95
• 57 Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S. et al. “BRC Aness” syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26: 5530-6
• 58 Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC. et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007; 43: 867-76
• 59 Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ. et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24: 2437-43
• 60 Robson M, Svahn T, McCormick B, Borgen P, Hudis CA, Norton L. et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic-based series. Cancer 2005; 103: 44-51
• 61 Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS. et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: Comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010; 121: 389-98
• 62 Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI. et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol 2015; 1: 306-13
• 63 Ashworth A. A synthetic lethal therapeutic approach: Poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 3785-90
• 64 Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005; 434: 913-7
• 65 Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21
• 66 Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377: 523-33
• 67 McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-15
• 68 McGrail DJ, Lin CC, Garnett J, Liu Q, Mo W, Dai H. et al. Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. NPJ Syst Biol Appl 2017; 3: 8
• 69 Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T. et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012; 72: 5454-62
• 70 Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012; 107: 1776-82
• 71 Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R. et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012; 2: 366-75
• 72 Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ. et al. TBCRC009: A Multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015; 33: 1902-9
• 73 Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC. et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016; 22: 3764-73
• 74 Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med 2017; 23: 517-25